Discovery^® HS C18 HPLC Column

SUPELCO/569251-U - 3 μm particle size, L × I.D. 7.5 cm × 4.6 mm

Synonym: Discovery RP18 HPLC Column

Product Type: Equipment/Book

Catalog Number	PKG Qty.	Price


45-569251-U	1 ea	$895.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

agency	suitable for USP L1
application(s)	food and beverages
extent of labeling	20% Carbon loading
feature	endcapped
impurities	<10 ppm metals
L × I.D.	7.5 cm × 4.6 mm
manufacturer/tradename	Discovery^®
material	stainless steel column
matrix	silica gel, high purity, spherical particle platform
	fully porous particle
matrix active group	C18 (octadecyl) phase
operating pH range	2-8
packaging	1 ea of
parameter	≤70 °C temp. range
	400 bar pressure (5801 psi)
particle size	3 μm
pore size	120 Å
product line	Discovery^®
Quality Level	100
separation technique	reversed phase
surface area	300 m²/g
surface coverage	3.2 μmol/m²
technique(s)	HPLC: suitable
	LC/MS: suitable

Application:	A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This research demonstrates the use of the Discovery^® HS C18 HPLC Column in developing a robust HPLC method for analyzing molnupiravir, showcasing its importance in current pandemic-related pharmaceutical research (Recber et al., 2022 ). A new RP-HPLC method as an auxiliary tool for optimization of sample preparation procedures for tracing of PPCPs of different hydrophilicities.: Highlights the adaptability of the Discovery^® HS C18 HPLC Column in environmental monitoring, specifically for pharmaceutical and personal care products, enhancing analytical methods for environmental safety (Portillo-Castillo et al., 2021 ). Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This study uses the Discovery^® HS C18 HPLC Column to assess terizidone levels in patient plasma, providing critical insights into the treatment of drug-resistant tuberculosis (Mulubwa and Mugabo, 2018 ). Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: Depicts the utility of the Discovery^® HS C18 HPLC Column in optimizing liquid chromatography methods for the potent chemotherapeutic agent doxorubicin, underscoring its role in therapeutic drug monitoring (Maliszewska et al., 2018 ). Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV.: Showcases the Discovery^® HS C18 HPLC Column′s application in studying the permeability and transport of efavirenz across the placenta, providing valuable pharmacological insights (Zelena et al., 2017 ).
Features and Benefits:	• Stable, low bleed for LC-MS applications • Scalable from analytical to preparatory • Highly stable to ensure excellent run-to-run and lot-to-lot reproducibility • Higher hydrophobicity for better resolution of difficult analytes
General description:	Discovery^® HS C18 HPLC column (L × I.D. 7.5 cm × 4.6 mm) is generally found to be stable under acidic and basic conditions.
Legal Information:	Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Recommended products:	Discover LiChropur reagents ideal for HPLC or LC-MS analysis

WGK Germany	WGK 1
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

UNSPSC

41115700

To Order From a Quote